Literature DB >> 18410610

Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival.

Peti Thuwajit1, Watinee Chawengrattanachot, Chanitra Thuwajit, Banchob Sripa, Anucha Paupairoj, Siri Chau-In.   

Abstract

BACKGROUND AND AIM: Cholangiocarcinoma (CCA) is a mucin-producing cancer that has poor prognosis. Mucin 6 (MUC6) is a mucin that is normally co-expressed with the trefoil factor family-2 (TFF2) trefoil peptide. Both MUC6 and TFF2 have been reported to be involved in the progression of many types of cancers. The aim of this study was to determine the expression of MUC6 and TFF2 in CCA tissues and associate these results with clinical data.
METHODS: MUC6 and TFF2 were detected in CCA tissues by immunohistochemistry. The correlations of MUC6 and TFF2 expressions with clinical data were analyzed.
RESULTS: We determined the significant co-expression of both proteins in serial CCA tissues. The high expressions of MUC6 and TFF2 were demonstrated in 37% and 31% of patients, respectively. The expression levels decreased in the advanced stage of CCA when clinical metastasis was exhibited. The high expression of either protein showed a correlation with prolonged postoperative survival time, but only a high expression of MUC6 is significantly correlated with a 5-year survival rate. A multivariate Cox regression analysis revealed that a low expression of MUC6, high expression of TFF2, age of patients >56 years, tumor size >5 cm, and poorly-differentiated histological type were independent, poor prognostic indicators for CCA.
CONCLUSION: MUC6 showed a good correlation with the survival of CCA patients. It may be of value to propose that MUC6 is a good prognostic marker for CCA management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410610     DOI: 10.1111/j.1440-1746.2008.05332.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

Review 1.  Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.

Authors:  Amir A Rahnemai-Azar; Pallavi Pandey; Ihab Kamel; Timothy M Pawlik
Journal:  Hepat Oncol       Date:  2017-01-20

2.  Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice.

Authors:  S Kongpetch; A Puapairoj; C K Ong; L Senggunprai; A Prawan; U Kukongviriyapan; W Chan-On; E Y Siew; N Khuntikeo; B T Teh; V Kukongviriyapan
Journal:  Cell Prolif       Date:  2016-01-04       Impact factor: 6.831

3.  Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma.

Authors:  Ji Eun Choi; Sang Jae Noh; Ju Hyung Lee; Jun Sang Bae; Hyun Hee Chu; Ho Sung Park; Kyu Yun Jang; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Woo Sung Moon
Journal:  Oncol Lett       Date:  2012-06-13       Impact factor: 2.967

Review 4.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

5.  Prognostic Factors for Surgically Resected Intraductal Papillary Neoplasm of the Bile Duct: A Retrospective Cohort Study.

Authors:  Shuichiro Uemura; Ryota Higuchi; Takehisa Yazawa; Wataru Izumo; Yutaro Matsunaga; Masahiro Shiihara; Takehiro Ota; Toru Furukawa; Masakazu Yamamoto
Journal:  Ann Surg Oncol       Date:  2020-07-10       Impact factor: 5.344

6.  A novel TFF2 splice variant (∆EX2TFF2) correlates with longer overall survival time in cholangiocarcinoma.

Authors:  Surasee Kamlua; Siriporn Patrakitkomjorn; Patcharee Jearanaikoon; Trevelyan R Menheniott; Andrew S Giraud; Temduang Limpaiboon
Journal:  Oncol Rep       Date:  2011-12-07       Impact factor: 3.906

Review 7.  Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Marcel Tantau; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.